## Sara Piccinin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6217740/publications.pdf

Version: 2024-02-01

28	3,732	18	23
papers	citations	h-index	g-index
31	31	31	6119
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Interference of p53:Twist1 interaction through competing nanobodies. International Journal of Biological Macromolecules, 2022, 194, 24-31.	7.5	4
2	The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways. Pharmaceutics, 2022, 14, 590.	4.5	11
3	Myoepithelial tumours of soft tissues and extraskeletal myxoid chondrosarcomas feature a distinct transcriptional pattern. Annals of Oncology, 2019, 30, v704.	1.2	0
4	Lowâ€dose radiotherapy in diffuse large Bâ€cell lymphoma. Hematological Oncology, 2017, 35, 472-479.	1.7	9
5	<i>miR-135a</i> Inhibits Cancer Stem Cell-Driven Medulloblastoma Development by Directly Repressing <i>Arhgef6</i> Expression. Stem Cells, 2015, 33, 1377-1389.	3.2	35
6	CDC25A Protein Stability Represents a Previously Unrecognized Target of HER2 Signaling in Human Breast Cancer: Implication for a Potential Clinical Relevance in Trastuzumab Treatment. Neoplasia, 2013, 15, 579-590.	5.3	18
7	<i>SMARCB1</i> / <i>INI1</i> /i> Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ. Molecular Cancer Therapeutics, 2013, 12, 1060-1072.	4.1	46
8	MEF2 Is a Converging Hub for Histone Deacetylase 4 and Phosphatidylinositol 3-Kinase/Akt-Induced Transformation. Molecular and Cellular Biology, 2013, 33, 4473-4491.	2.3	48
9	351 A Twist1 Code of P53 Inactivation. European Journal of Cancer, 2012, 48, S86.	2.8	O
10	A "Twist box―Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation. Cancer Cell, 2012, 22, 404-415.	16.8	106
11	Abstract 290: A Twist1 code of p53 inactivation. , 2012, , .		0
12	Overexpression of TWIST2 correlates with poor prognosis in Head and Neck Squamous Cell Carcinomas. Oncotarget, 2011, 2, 1165-1175.	1.8	54
13	TWIST1 Plays a Pleiotropic Role in Determining the Anaplastic Thyroid Cancer Phenotype. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E772-E781.	3.6	39
14	Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites. International Journal of Cancer, 2008, 123, 1466-1471.	5.1	16
15	Induction of EMT by Twist Proteins as a Collateral Effect of Tumor-Promoting Inactivation of Premature Senescence. Cancer Cell, 2008, 14, 79-89.	16.8	633
16	Fra2 is an antagonist of p53. European Journal of Cancer, Supplement, 2008, 6, 125.	2.2	0
17	Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 2006, 444, 638-642.	27.8	1,576
18	Twist is substrate for caspase cleavage and proteasome-mediated degradation. Cell Death and Differentiation, 2006, 13, 335-345.	11.2	48

#	Article	IF	CITATION
19	Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. Oncogene, 2005, 24, 2483-2494.	5.9	22
20	Alterations of $\hat{l}^2$ -Catenin Pathway in Non-Melanoma Skin Tumors. American Journal of Pathology, 2003, 163, 2277-2287.	3.8	329
21	Transformation of normal human cells in the absence of telomerase activation. Cancer Cell, 2002, 2, 401-413.	16.8	143
22	Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. Journal of Pathology, 2000, 190, 531-536.	4.5	250
23	Microsatellite instability in squamous cell carcinomas of the head and neck related to field cancerization phenomena. British Journal of Cancer, 1998, 78, 1147-1151.	6.4	49
24	Human Non-Hodgkin's Lymphomas Overexpress a Wild-Type Form of p53 Which Is a Functional Transcriptional Activator of the Cyclin-Dependent Kinase Inhibitor p21. Blood, 1997, 89, 2523-2528.	1.4	32
25	MOLECULAR ABNORMALITIES OF THE p53 PATHWAY IN DEDIFFERENTIATED LIPOSARCOMA. Journal of Pathology, 1997, 181, 8-13.	4.5	80
26	p16/CDKN2 andCDK4 gene mutations in sporadic melanoma development and progression. International Journal of Cancer, 1997, 74, 26-30.	5.1	74
27	Recurrences and second primary tumours in the head and neck region: Differentiation by p53 mutation analysis. Annals of Oncology, 1995, 6, 933-939.	1.2	20
28	Spontaneous Mutation of Cell Oncogenes Plays a Minor Role in Neoplastic Transformation of Virus-Induced Murine T-Cell Lymphomas. Tumori, 1995, 81, 268-272.	1.1	0